Latest From Repligen Corp.
Device and diagnostics fundraising slumped in Q2, but there was a substantial uptick in M&A activity. Device financings totaled just slightly over half of the previous quarter, while acquisitions grew almost six-fold, thanks primarily to Becton Dickinson's $23.5 billion play for CR Bard. Financing in diagnostics slid to $1.03 billion, less than half of Q1, whereas the $1.7 billion in M&As (most of that from PerkinElmer's $1.3 billion buy of EuroImmun) was more than double Q1's aggregate.
A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
Allergan rebounded from the derailed Pfizer acquisition by signing a $3 billion partnership with Heptares to develop small-molecule muscarinic receptor agonists in CNS diseases; there was a huge consolidation in cardiovascular devices through Abbott's $25 billion purchase of St. Jude Medical. Biopharma funding totaled $1.1 billion, while device fundraising reached $248 million.
- Synthesis Technologies, Production Processes
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Repligen Corp.
- RepliGen Corp.
- Senior Management
Tony J Hunt, Pres. & CEO
Jon K Snodgres, CFO
Ralf R Kuriyel, SVP, R&D
Stephen A Tingley, VP, Sales
Marc Centrella, VP, Bus. Dev. & Strategy
Rachel Goodrich, VP, Mktg.
- Contact Info
Phone: (781) 250-0111
41 Seyon St., Bldg. #1
Waltham, MA 02453
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.